Pioneering evidence-based longevity care
Circulate Health was founded on a simple belief: that advanced, science-based care should be safe, consistent, and accessible.
Our Mission
Circulate Health is redefining how longevity care is delivered and experienced. Today, we enable clinics to deliver TPE to patients seeking science-based ways to extend healthspan. But our mission doesn’t stop there. We’re committed to advancing longevity science, expanding research, exploring new indications, and building the evidence base that will define the future of clinical longevity care.
Our Team
Spanning diverse backgrounds and disciplines, the Circulate team is passionate about enabling successful outcomes for partners and patients.
Brad Younggren MD
Co-Founder, CEO
Eric Verdin MD, PhD
Co-Founder, CEO Buck Institute
Robbie Schwietzer
Chief Operating Officer
Jenna Walcott
Chief Marketing Officer
Chrissy Anderson
Chief Nursing Officer
Amin Neghabat
Chief Business Officer
Bob Weinstein MD
Vice President Apheresis
Stella Yuksel
Director of Bioengineering
Ethan Diamond
Head of Product
Scientific Advisors
Our work is guided by leading researchers and clinicians at the forefront of longevity science.
David Furman PhD
Advisor,
Director Buck Institute
Alex Aravanis MD PhD
Advisor,
CEO Moonwalk Biosciences
Matt Kaeberlein PhD
Advisor,
Professor University of Washington
Matthew Campen PhD
Scientific Advisory Board
Our Journey
The science behind Circulate started with a question: what if targeting factors in the blood could influence how we age? The Circulate Trial answered it, becoming the first human study to demonstrate a measurable reduction in biological age following TPE.
Building on two decades of research, the team focused on developing safe, effective treatments grounded in rigorous scientific methods. The apheresis device used for TPE is FDA-cleared, and the American Society for Apheresis has published clinical practice guidelines classifying conditions based on the strength of evidence and effectiveness of TPE.
The Circulate Trial
Circulate conducted the first-of-its-kind, single-blind human clinical trial to evaluate how TPE, with and without IVIG, may influence biological age and immune markers associated with longevity. This landmark, peer-reviewed study, published in Aging Cell, showed an average 2.6-year reduction in biological age after six sessions.
2.6 years: average biological age reduction after six TPE sessions.*
*Source: Aging Cell (2025). Study by Fuentealba et al.
Significant reduction in circulating microplastics in patients with starting levels ≥30 per 100 µL (p<0.001).*
*Source: Circulate Health study, 174 TPE procedures on 114 subjects.
Microplastics Research
Circulate conducted the first study to demonstrate that therapeutic plasma exchange can effectively reduce circulating microplastics from the bloodstream. In patients with elevated levels, TPE achieved a statistically significant decrease in microplastic burden, offering a potential pathway to address a growing public health concern.
In the Press
